Australia's TGA Said To Get Application To Market RU486 Drug
This article was originally published in PharmAsia News
Executive Summary
Australia's Therapeutic Goods Administration allegedly has received an application from a drug maker to market RU486 (mefipristone), intended for aborting a fetus up to nine weeks following conception